Vincristine sulfate
(Synonyms: 硫酸长春新碱; Leurocristine sulfate; NSC-67574 sulfate; 22-Oxovincaleukoblastine sulfate) 目录号 : GC11511
An antimitotic inhibitor of tubulin polymerization
Cas No.:2068-78-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
| Cell experiment [1]: | |
|
Cell lines |
B16 melanoma cell |
|
Preparation method |
The solubility of this compound in DMSO is > 10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 °C for several months. |
|
Reacting condition |
10 ~ 100 nM; 3 days |
|
Applications |
In B16 melanoma cells, Vincristine inhibited the tubulin addition at assembly ends of steady-state microtubules with the Ki value of 85 nM. |
| Animal experiment [2]: | |
|
Animal models |
Mice bearing human rhabdomyosarcoma xenografts Rh12 or Rh18 |
|
Dosage form |
3 mg/kg; i.p.; a single dose |
|
Applications |
In mice bearing human rhabdomyosarcoma xenografts Rh12 or Rh18, Vincristine (3 mg/kg, i.p., a single dose) induced mean growth delay of > 120 and > 52 days, as well as repopulating fractions of 0.06% and 5%, respectively. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1]. Jordan MA, Himes RH, Wilson L. Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro. Cancer Res. 1985 Jun;45(6):2741-7. [2]. Baguley BC, Holdaway KM, Thomsen LL, Zhuang L, Zwi LJ. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer. 1991;27(4):482-7. |
|
Vincristine is a naturally occurring alkaloid that potently inhibits the tubulin addition with the inhibition constant Ki value of 0.085 μM and exhibits an anti-proliferative activity against B16 melanoma cells with the half maximal inhibition concentration IC50 value of 0.45 M [1].
Vincristine is extracted from leaves of the periwinkle plant Catharanthus roseus (L.) G. Don of the family Apocynaceae and has an asymmetric structure consisting of two dimers, a dihydroindole nucleus (vindoline) and an indole nucleus (catharanthine), that are linked by a carbon-carbon bond [2].
Vincristine has been found to be active against a wild range of malignancies, including acute lymphoblastic leukemia (ALL), acute non-lymphoblastic leukemia (ANLL), non-Hodgkin lymphoma (NHL), Hodgkin’s disease and brain tumors [2].
References:
[1] Jordan MA, Himes RH, Wilson L. Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro. Cancer Res. 1985 Jun;45(6):2741-7.
[2] Gidding CE1, Kellie SJ, Kamps WA, de Graaf SS. Vincristine revisited. Crit Rev Oncol Hematol. 1999 Feb;29(3):267-87.
| Cas No. | 2068-78-2 | SDF | |
| 别名 | 硫酸长春新碱; Leurocristine sulfate; NSC-67574 sulfate; 22-Oxovincaleukoblastine sulfate | ||
| Canonical SMILES | O[C@]1(CC)CN(CC2)C[C@@](C1)([H])C[C@](C(OC)=O)(C3=C(OC)C=C(N(C=O)[C@]4([H])[C@@]56C7[C@](C=CCN7CC6)(CC)C(OC(C)=O)[C@@]4(C(OC)=O)O)C5=C3)C8=C2C9=CC=CC=C9N8.OS(O)(=O)=O | ||
| 分子式 | C46H58N4O14S | 分子量 | 923.04 |
| 溶解度 | ≥ 46.15mg/mL in DMSO;>50mg/mL in water | 储存条件 | 4°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.0834 mL | 5.4169 mL | 10.8338 mL |
| 5 mM | 0.2167 mL | 1.0834 mL | 2.1668 mL |
| 10 mM | 0.1083 mL | 0.5417 mL | 1.0834 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。